Cargando…
Successful desensitization to high dose rituximab for a child with nephrotic syndrome – The first report in the literature
Rituximab is a chimeric monoclonal antibody, which is mainly used in the treatment of lymphoma and autoimmune disorders, but also has been recently approved for the treatment of nephrotic syndrome. The treatment dose is between 375 mg/m(2) and 750 mg/m(2). Rituximab has been associated with hypersen...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Asia Pacific Association of Allergy, Asthma and Clinical Immunology
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563104/ https://www.ncbi.nlm.nih.gov/pubmed/34786367 http://dx.doi.org/10.5415/apallergy.2021.11.e37 |